Building a robust investment portfolio hinges on identifying undervalued opportunities. Astute investors seek stocks priced below their intrinsic value yet possessing strong growth potential – essentially, finding diamonds in the rough within the equity market. Share prices can decline for various reasons, from temporary market fluctuations to fundamental company issues. Discerning between temporary setbacks and inherent problems is crucial for successful investing. This article delves into two such companies, each experiencing a significant drop in share price this year, yet backed by Wall Street analysts for a potential rebound in 2025. Leveraging insights from the TipRanks platform, we’ll explore why these stocks warrant a closer look.
Table Content:
Identifying Potential with Data and Judgment
Successfully pinpointing stocks with depressed prices and solid fundamentals necessitates reliable data coupled with sound judgment. Utilizing the TipRanks platform, we’ve identified two compelling investment prospects, both down over 60% year-to-date. Let’s analyze these companies in detail.
Quanterix (QTRX): Revolutionizing Biomarker Analysis
Quanterix operates in the life sciences sector, pioneering the digitization of biomarker analysis to advance precision health. The company aims to facilitate earlier disease detection, improved prognoses, and targeted treatment strategies across oncology, neurology, cardiology, inflammatory, and infectious diseases. Quanterix’s proprietary Simoa technology underpins its commercial brand, Lucent Diagnostics, focused on early detection of cognitive diseases. Early diagnosis is paramount for these challenging conditions, as treatments are more effective when initiated early.
Recently, Quanterix announced the acquisition of Emission, a smaller immunoassay testing company, for up to $70 million. This strategic move, expected to close in January 2025, is projected to boost revenues from 2026 onwards. Despite reporting a Q3 2024 net loss of -$11.2 million, Quanterix achieved its sixth consecutive quarter of double-digit revenue growth, reaching $35.7 million, exceeding forecasts by $1.5 million. However, the market reaction has been muted, with share prices declining further. Despite a year-to-date drop of 61.5%, Canaccord Genuity analyst Kyle Mikson views QTRX as undervalued, citing the company’s new product development, Lucent brand expansion, and anticipated double-digit revenue growth as key drivers. Mikson assigns a Buy rating with a $20 price target, implying a 90% upside potential.
The overall analyst consensus rates QTRX as a Strong Buy, with an average price target of $22.25, suggesting a potential 111.5% upside.
Green Plains, Inc. (GPRE): Leading the Biofuel Revolution
Green Plains is a prominent bio-refining company specializing in the development and production of low-carbon biofuels. With ten biorefineries across the US, Green Plains processes vast quantities of corn to produce biofuel, renewable corn oil, and distillers grains. Beyond biofuels, the company’s diversified portfolio includes proteins and ingredients for pet food, renewable corn oil for biofuel refining, and various glucose and dextrose syrups for industrial applications. Green Plains also operates a robust transportation and logistics network encompassing grain and biofuel storage, fuel terminals, and fuel transport services.
While Q3 2024 results revealed a revenue miss of $658.7 million (down 26% year-over-year) and earnings of 69 cents per share (beating expectations by 57 cents), GPRE’s share price has plummeted 63% this year. Truist analyst Jordan Levy remains optimistic, believing Green Plains is poised for accelerated growth. Levy highlights the company’s improved operational performance, favorable crush spread environment, and progress in key areas like Sequence sales, CST ramp, and Nebraska CCUS. He maintains a Buy rating with an $18 price target, projecting a 95% upside.
Mirroring the sentiment on Quanterix, GPRE holds a Strong Buy consensus rating with an average price target of $18, implying a potential 95% return.
Conclusion: Navigating Market Volatility
Identifying undervalued stocks with strong growth potential requires diligent research and a keen understanding of market dynamics. Quanterix and Green Plains, despite their recent price declines, present compelling investment opportunities based on their innovative technologies, expanding markets, and positive analyst outlooks. While market volatility persists, these two companies demonstrate the potential for significant rebounds in 2025. For further insights into undervalued stocks, explore TipRanks’ Best Stocks to Buy tool.
